A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors - Trial NCT06417554
Access comprehensive clinical trial information for NCT06417554 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shanghai Hengrui Pharmaceutical Co., Ltd.
Timeline & Enrollment
Phase 1/2
May 01, 2024
Jul 01, 2027
Primary Outcome
RP2D,Incidence and severity of AE๏ผ,ORR
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102
 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the
 reasonable dosage of SHR-A2102 for Advanced Solid Tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06417554
Non-Device Trial